High Evidence
Research Overview
Survodutide Research for Type 2 Diabetes
An evidence-based overview of research examining Survodutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 RCT (N=411) demonstrated HbA1c reduction of 1.9% at 16 weeks vs semaglutide 1mg (1.4%) and placebo (0.1%). Weight loss also superior to semaglutide at 9.6% vs 5.1%.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Survodutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.